| Literature DB >> 34805099 |
Jiao-Jiao Zhang1,2, Dai-Wei Wang1, Dan Cai1, Qing Lu1,3, Yong-Xian Cheng1,3.
Abstract
Ganoderma fungi as popular raw materials of numerous functional foods have been extensively investigated. In this study, five pairs of meroterpenoid enantiomers beyond well-known triterpenoids and polysaccharides, dayaolingzhiols I-M (1-5), were characterized from Ganoderma lucidum. Their structures were identified using spectroscopic and computational methods. Structurally, compound 1 features a novel dioxabicyclo[2.2.2]octan-3-one motif in the side chain. Ethnoknowledge-derived biological evaluation found that (+)-5 could activate Akt and AMPK phosphorylation in insulin-stimulated C2C12 cells, and (+)-5 could activate glucose uptake dose dependently in C2C12 cells. Furthermore, we found that (+)-1 (+)-4, and (-)-4 could significantly inhibit cell migration of the MDA-MB-231 cell line, of which (+)-4 showed significant inhibitory effects against cell migration of the MDA-MB-231 cell line in a dose-dependent manner. These findings revealed the meroterpenoidal composition of G. lucidum and its roles in the prevention of chronic diseases such as diabetes mellitus and triple-negative breast cancer.Entities:
Keywords: AMPK phosphorylation; Akt phosphorylation; Ganoderma lucidum; cell migration; glucose uptake; meroterpenoids
Year: 2021 PMID: 34805099 PMCID: PMC8595597 DOI: 10.3389/fchem.2021.772740
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
FIGURE 1Structures of 1–5 from Ganoderma lucidum.
1H (600 MHz) and 13C NMR (150 MHz) data of 1 and 2 in methanol-d 4 (δ in ppm, J in Hz).
| No. | 1 | 2 | ||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | 156.8 s | 154.1 s | ||
| 2 | 121.5 s | 125.0 s | ||
| 3 | 7.27 d (2.9) | 116.7 d | 6.92 d (2.5) | 104.0 d |
| 4 | 150.5 s | 148.5 s | ||
| 5 | 7.00 dd (8.9, 2.9) | 126.0 d | 6.72 dd (8.8, 2.5) | 113.9 d |
| 6 | 6.78 d (8.9) | 119.5 d | 7.18 d (8.8) | 119.7 d |
| 7 | 203.8 s | 141.1 s | ||
| 8 | Ha: 3.52 d (15.8) | 42.7 t | 144.2 s | |
| Hb: 3.15 d (15.8) | ||||
| 9 | 74.4 s | 3.87 dd (8.5, 6.0) | 43.6 d | |
| 10 | 173.9 s | 175.7 s | ||
| 11 | Ha: 2.22 overlap | 27.8 t | 2.06 overlap | 30.8 t |
| Hb: 2.09 m | 2.00 overlap | |||
| 12 | Ha: 2.22 overlap | 22.4 t | 2.00 overlap | 26.7 t |
| Hb: 2.02 m | ||||
| 13 | 4.55 dd (3.0, 1.7) | 81.1 d | 5.11 t (7.0) | 124.4 days |
| 14 | 78.6 s | 137.4 s | ||
| 15 | 1.24 s | 22.4 q | 1.52 s | 16.1 q |
| 16 | 1.53 overlap | 40.1 t | 1.96 t (7.5) | 40.8 t |
| 17 | 1.94 m | 23.6 t | 2.06 overlap | 27.7 t |
| 18 | 5.06 t (7.3) | 124.8 d | 5.10 t (7.1) | 125.4 d |
| 19 | 133.0 s | 132.2 s | ||
| 20 | 1.64 s | 25.8 q | 1.67 s | 25.9 q |
| 21 | 1.51 s | 17.6 q | 1.60 s | 17.8 q |
| -OCH3 | 3.90 s | 61.5 q | ||
| 1-OH | 11.06 s | |||
| 4-OH | 9.14 s | |||
These signals are observed in DMSO-d6.
FIGURE 2Key 1H–1H COSY, HMBC, and ROESY correlations of 1–5.
FIGURE 3Comparison of the calculated ECD spectrum of 1 at the PBE1PBE/def2SVP level with the experimental one in MeOH. σ = 0.25 eV; shift = 13 nm.
FIGURE 4Comparison of the calculated ECD spectrum of 2 at the APFD/6–311+ g (2 d,p) level with the experimental one in MeOH. σ = 0.25 eV; shift = −25 nm.
1H and 13C NMR data of 3 and 4 in methanol-d 4 (δ in ppm, J in Hz).
| No | 3 | 4 | ||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | 148.9 s | 156.5 s | ||
| 2 | 123.5 s | 120.3 s | ||
| 3 | 6.46 d (2.9) | 113.3 d | 7.25 d (2.9) | 115.4 d |
| 4 | 151.5 s | 150.6 s | ||
| 5 | 6.61 dd (8.7, 2.9) | 117.2 d | 7.01 dd (8.9, 2.9) | 125.9 d |
| 6 | 6.68 d (8.7) | 117.2 d | 6.79 d (8.9) | 119.7 d |
| 7 | 6.23 d (1.6) | 79.8 d | 205.5 s | |
| 8 | 7.35 d (1.6) | 151.1 d | Ha: 3.43 dd (17.9, 9.6) | 41.4 t |
| Hb: 3.17 dd (17.9, 4.3) | ||||
| 9 | 133.1 s | 2.99 m | 41.0 d | |
| 10 | 176.8 s | 177.7 s | ||
| 11 | 2.35 t (7.7) | 26.2 t | Ha: 1.73 m | 33.1 t |
| Hb: 1.64 m | ||||
| 12 | 2.30 m | 26.9 t | 2.08 overlap | 26.4 t |
| 13 | 5.14 t (7.0) | 124.1 d | 5.13 t (7.6) | 124.5 d |
| 14 | 137.9 s | 137.3 s | ||
| 15 | 1.58 s | 16.1 q | 1.61 s | 16.1 q |
| 16 | 1.96 t (7.1) | 41.1 t | 2.00 t (7.5) | 40.8 t |
| 17 | 1.43 m | 23.6 t | 2.08 overlap | 27.6 t |
| 18 | 1.38 m | 44.3 t | 5.09 t (7.0) | 125.3 d |
| 19 | 71.5 s | 132.2 s | ||
| 20 | 1.15 overlap | 29.2 q | 1.66 s | 25.9 q |
| 21 | 1.15 overlap | 29.2 q | 1.59 s | 17.8 q |
| -OCH3 | 3.68 s | 52.3 q | ||
1H recorded at 600 MHz and 13C NMR recorded at 150 MHz (compound 3).
1H recorded at 500 MHz and 13C NMR recorded at 125 MHz (compound 4).
1H (500 MHz) and 13C NMR (125 MHz) data of 5 in methanol-d 4 (δ in ppm, J in Hz).
| No. |
|
| No. |
|
|
|---|---|---|---|---|---|
| 1 | 156.6 s | 12 | Ha: 2.23 m | 22.9 t | |
| 2 | 120.8 s | Hb: 2.00 overlap | |||
| 3 | 7.22 d (2.9) | 115.7 d | 13 | 5.14 t-like (6.8) | 124.7 d |
| 4 | 150.7 s | 14 | 136.9 s | ||
| 5 | 7.01 d (8.9, 2.9) | 126.1 d | 15 | 1.62 s | 16.0 q |
| 6 | 6.79 d (8.9) | 119.7 d | 16 | 2.00 overlap | 40.8 |
| 7 | 204.8 s | 17 | 2.08 m | 27.7 t | |
| 8 | Ha: 3.54 d (17.3) | 48.4 t | 18 | 5.10 t (7.0) | 125.4 d |
| Hb: 3.45 d (17.3) | 19 | 132.2 s | |||
| 9 | 75.8 s | 20 | 1.67 s | 25.9 q | |
| 10 | 178.6 s | 21 | 1.60 s | 17.8 q | |
| 11 | 1.78 m | 41.0 |
Signals with the same symbol might be interchangeable.
FIGURE 5Comparison of the calculated ECD spectrum of 5 at the PBE1PBE/def2SVP level with the experimental one in MeOH. σ = 0.25 eV; shift = 0 nm.
FIGURE 6Effects of the compounds on insulin-induced insulin resistance in myotubes. (A–C) Compounds attenuated insulin signal pathway disruption. Bar graphs show the quantification of the indicated proteins. # p < 0.05 and ## p < 0.01 compared with without insulin treatment control; * p < 0.05 and ** p < 0.01 compared with insulin treatment alone. (D) Compound (+)-5 improved insulin-stimulated glucose uptake in myotubes. #### p < 0.0001 compared with without insulin-stimulated control; **** p < 0.0001 compared with the insulin treatment group; $$$$ p < 0.0001 compared with insulin treatment alone.
FIGURE 7Effects of compounds on cell migration at low-toxicity doses. (A) Cell viability of MDA-MB-231 was treated with the vehicle or 20 μM compounds for 48 h (n = 3). (B) Wound healing assay of the MDA-MB-231 cell line, treated with the vehicle or 20 μM compounds for 24 h (n = 3). (C) The dose-dependent migratory inhibition effect of the compound (+)-4. (D) Representative pictures of compounds (+)-1 (+)-4 and (–)-4 at 20 μM for 24 h of MDA-MB-231. (E) Representative pictures of compound (+)-4 at different doses for 24 h in MDA-MB-231 cells. Data are of three replicates (n = 3) * p < 0.05, ** p < 0.01, one-way ANOVA.